Incannex Healthcare, Inc. (MUM.AU) Stock Price, Financials & Summary

Key data

Open—

From 52W high—

Volume—

Market cap—

P/E (TTM)—

P/S (TTM)—

Div yield—

Key data

Open

—

From 52W high

—

Volume

—

Market cap

—

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

—

MomentumView details →

1D Return

—

YTD Return

—

SummaryUpdated Mar 1, 2026

Incannex Healthcare Limited (ASX:IXHL) is an Australian pharmaceutical company that develops medicinal cannabinoid products for various medical conditions. Founded in 2001 and originally known as Impression Healthcare Limited, the company rebranded to Incannex Healthcare in June 2020 to reflect its focus on cannabinoid-based therapeutics. The company went public on the Australian Securities Exchange in March 2022. Incannex is currently in the clinical development phase, with multiple drug candidates in various stages of trials targeting conditions such as obstructive sleep apnea, traumatic brain injury, and inflammatory diseases.

Ask drillr about Incannex Healthcare, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

—

YTD Return

—

1Y Return

—

RSI (14)

—

vs 50D SMA

—

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

66616.00

Net Income (TTM)

−49.94M

Op. CF (TTM)

—

Latest newsMore news →

Incannex Healthcare commenced patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea.11d ago

Incannex Healthcare was granted a U.S. composition and methods of treatment patent covering IHL-42X with baseline expiry in 2040.11d ago

Latest newsMore news →

Incannex Healthcare commenced patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea.11d ago Incannex Healthcare was granted a U.S. composition and methods of treatment patent covering IHL-42X with baseline expiry in 2040.11d ago